Nasdaq: SNGX

Download the recent Soligenix CEO Q&A on Positive Phase 3 CTCL Data and The Covid 19 Program

Soligenix is a client of PCG Advisory, Inc., an investor relations and communications firm. Please see our disclosures on our website

 © Soligenix, 2020. All Rights Reserved. 

Soligenix is a late-stage biopharmaceutical company that seeks to fulfill unmet needs in the medical field by developing and commercializing products to treat rare diseases. The company has two distinct business segments: Specialized BioTherapeutics, focusing on oncology and inflammation, and Public Health Solutions, focusing on federally funded vaccine developments.

Together, these two business arms create an environment ripe for opportunity with major milestones expected in the coming months.

Rising to the challenges of rare disease treatment

Diversifying platforms with successful public health initiatives.

In addition to the company’s oncology treatment initiatives, Soligenix has developed a robust pipeline with its Public Health Solutions arm.  It’s currently operating under multiple grant and contract awards, the largest being a contract award of up to $24.7 million with the NIH to produce a heat stable ricin vaccine called RiVax®

In recent news Soligenix Public Health Segment related to advances in its RiVax® program may earn attraction as governments around the world take a lesson from the COVID-19 pandemic to stock up public health product inventories


Phase 3 studies bring two new treatments closer to market.

Soligenix currently has two promising treatments in Phase 3 clinical trials. The first is SGX301, which completed patient enrollment at the end of last year. It’s designed to treat patients with cutaneous T cell lymphoma (CTCL), a rare form of cancer. Positive Top-line results from the trial were released on March 19.

The second program actively enrolling in a Phase 3 clinical trial is SGX942, which treats oral mucositis, a serious side effect caused by radiation and chemotherapy, in patients with head and neck cancer. Enrollment for this trial will be completed in the first quarter of 2020, with top line results anticipated in 2020’s second quarter.

Positive interim analyses have already been completed for these two Phase 3 studies, in which an independent, unblinded data monitoring committee reviewed actual data from the clinical trials for both SGX301 and SGX942 and recommended to continue enrollment and  increase the total number of participants in each study in order to maintain the studies high statistical power.

The potential for medical breakthroughs for those with rare diseases.

Both of these treatments are poised to potentially change the lives of patients suffering from incredible medical challenges. CTCL is a painful form of skin cancer that results in lesions and tumors across the body. SGX301 (synthetic hypericin) is a unique topical ointment that is activated with a proprietary light device to kill the malignant T-cells.

SGX942 is designed to treat oral mucositis — a painful side effect of radiation chemotherapy experienced by head and neck cancer patients. Oral mucositis causes an exaggerated inflammation in the mouth, throat, and GI tract that makes it difficult to eat or drink. It’s so painful that many patients either temporarily or permanently stop their cancer treatment, resulting in poorer survival prognosis.

A short four-minute IV infusion that can be done alongside radiation chemotherapy twice a week, SGX942 offers new hope by reducing inflammation and clearing infection. Ultimately, it has the potential to make life more bearable for cancer patients while helping them complete their recommended radiation and/or chemotherapy treatment plans.

PCG Advisory logo
American Resources Corporation Logo

Soligenix is a client of PCG Advisory, Inc., an investor relations and communications firm. Please see our disclosures on our website

CEO Dr Christopher Schaber has 3 reasons why you should pay attention to Soligenix.

Soligenix Announces Phase 3 FLASH Study Continues to Demonstrate Positive Benefits in Patients with Cutaneous T-Cell Lymphoma

Read the full Release